Patents Assigned to Wyeth
  • Process for the preparation of 1,2,3,4,8,9,10,10a-octahydro-7bH-cyclopenta [B] [1,4] diazepino- [6,7,1-hi] indole derivatives
    Patent number: 6916922
    Abstract: This invention provides a process for the preparation of 1, 2, 3, 4, 8, 9, 10, 10a-octahydro-7bH-cyclopenta[b][1,4]diazepino[6,7,1-hi]indole derivatives of the general formula: wherein: R is H, alkyl, cycloalkyl, —CH2-cycloalkyl, acyl, aryl or aroyl; R1, R2, R4 and R5 are H, hydroxy, alkyl, cycloalkyl, alkoxy, halogen, fluorinated alkyl, —CN, —NH—SO2-alkyl, —SO2—NH-alkyl, alkyl amide, amino, alkylamino, dialkylmino, fluorinated alkoxy, acyl, aryl or aroyl; R3 is H, alkyl, cycloalkyl, alkoxy, fluorinated alkyl, alkyl sulfonamide, alkyl amide, amino, alkylamino, dialkylmino, fluorinated alkoxy, acyl, aryl or aroyl; or a pharmaceutically acceptable salt thereof, as well as intermediates for their synthesis.
    Type: Grant
    Filed: November 2, 2001
    Date of Patent: July 12, 2005
    Assignee: Wyeth
    Inventor: Anita W-Y. Chan
  • Synthetic methodology for the reductive alkylation at the C-3 position of indoles
    Publication number: 20050148770
    Abstract: A process for the reductive alkylation at the C-3 position of an indole compound in which the indole is treated with an aldehyde in the presence of a Lewis acid and a silicon hydride reducing agent. The process is useful for alkylating the C-3 position of indoles that contain acid-sensitive substituents at the N-1 position.
    Type: Application
    Filed: December 16, 2004
    Publication date: July 7, 2005
    Applicant: Wyeth
    Inventors: Ronald Michalak, Panolil Raveendranath
  • Arylalkyl-and cycloalkylalkyl-piperazine derivatives and methods of their use
    Publication number: 20050148595
    Abstract: The present invention is directed to arylalkyl- and cycloalkylalkyl-piperazine derivatives, compositions containing these derivatives, and methods of their use for the prevention and treatment of conditions ameliorated by monoamine reuptake including, inter alia, vasomotor symptoms (VMS), sexual dysfunction, gastrointestinal and genitourinary disorders, chronic fatigue syndrome, fibromylagia syndrome, nervous system disorders, and combinations thereof, particularly those conditions selected from the group consisting of major depressive disorder, vasomotor symptoms, stress and urge urinary incontinence, fibromyalgia, pain, diabetic neuropathy, and combinations thereof.
    Type: Application
    Filed: October 12, 2004
    Publication date: July 7, 2005
    Applicant: Wyeth
    Inventor: Paige Mahaney
  • Novel method of modulating bone-related activity
    Publication number: 20050148506
    Abstract: This invention relates to modulating bone-related activity in a subject by modulating Ror molecules. The invention further relates to compositions and methods for the screening, diagnosis and development of therapies for bone-related disorders. It is emphasized that this abstract is provided to comply with the rules requiring an abstract that will allow a searcher or other reader to quickly ascertain the subject matter of the technical disclosure. It is submitted with the understanding that it will not be used to interpret or limit the scope or meaning of the claims.
    Type: Application
    Filed: April 14, 2004
    Publication date: July 7, 2005
    Applicant: Wyeth
    Inventors: Julia Billiard, Peter Bodine
  • Glycopeptide antibiotics
    Patent number: 6914045
    Abstract: The invention provides compounds of formula Wherein R1, R2, R3, R4, R5, R6a, R6b, R6c, R6d, R6e and R7 are defined in the specification. These compounds are useful as antibiotic agents.
    Type: Grant
    Filed: April 25, 2002
    Date of Patent: July 5, 2005
    Assignee: Wyeth Holdings Corporation
    Inventors: Darren Robert Abbanat, Valerie Sue Bernan, Russell George Dushin, Michael Greenstein, Haiyin He, Stanley Albert Lang, Howard Newman, Subas Sakya, Phaik-Eng Sum, Alan Gordon Sutherland, Ting-Zhong Wang, Jason Arnold Lotvin, Mark Edward Ruppen, Arthur Emergy Bailey, Ping Cai, Bo Shen, Fangming Kong
  • Substituted phenyl naphthalenes as estrogenic agents
    Patent number: 6914074
    Abstract: This invention provides estrogen receptor modulators of formula I, having the structure wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, and R10, are as defined in the specification, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: December 11, 2002
    Date of Patent: July 5, 2005
    Assignee: Wyeth
    Inventors: Richard E. Mewshaw, Richard J. Edsall, Cuijian Yang, Heather A. Harris, James C. Keith, Jr., Leo M. Albert, Eric S. Manas
  • Infant formula compositions comprising increased amounts of alpha-lactalbumin
    Patent number: 6913778
    Abstract: An infant formula composition is provided comprising a whey fraction wherein 40% or less of the total protein in said fraction is alpha-lactalbumin and more than 8% of the total protein in said whey fraction is beta-lactoglobulin, with the proviso that the percentage of alpha-lactalbumin in said whey fraction is greater than the percentage of beta-lactoglobulin in said whey fraction.
    Type: Grant
    Filed: December 13, 2002
    Date of Patent: July 5, 2005
    Assignee: Wyeth
    Inventors: Charles F. Kuhlman, Eric Lien, John Weaber, Daniel O'Callaghan
  • Biaryl sulfonamides and methods for using same
    Publication number: 20050143422
    Abstract: The present invention relates to biaryl sulfonamides and their use as, for example, metalloproteinase inhibitors.
    Type: Application
    Filed: December 1, 2004
    Publication date: June 30, 2005
    Applicant: Wyeth
    Inventors: Jeremy Levin, Thomas Rush, Frank Lovering, Yonghan Hu, Jianchang Li, Wei Li, Jun Wu, Rajeev Hotchandani, Jason Xiang, Xuemei Du, Derek Cole, Steve Tam
  • Methods for reducing adverse effects of feeding formula to infants
    Publication number: 20050142249
    Abstract: Methods for reducing side-effects of feeding an individual are provided. The methods comprise administering to the individual a composition comprising an amount of bovine milk providing 1.0 to 1.2 grams of protein per 100 available kilocalories and an amount of a bovine whey material providing 1.0 to 1.2 grams of protein per 100 available kilocalories, said bovine whey material having an alpha-lactalbumin content of 28% to 40% and a beta-lactoglobulin content of 8% to 33% of total protein.
    Type: Application
    Filed: February 24, 2005
    Publication date: June 30, 2005
    Applicant: Wyeth
    Inventors: Anne Davis, Charles Kuhlman
  • Dihydrobenzofuranyl alkanamine derivatives and methods for using same
    Publication number: 20050143452
    Abstract: Compounds of Formula 1 or pharmaceutically acceptable salts thereof are provided: which are agonists or partial agonists of the 2C subtype of brain serotonin receptors. The compounds, and compositions containing the compounds, can be used to treat a variety of central nervous system disorders such as schizophrenia.
    Type: Application
    Filed: October 21, 2004
    Publication date: June 30, 2005
    Applicant: Wyeth
    Inventors: Jonathan Gross, Marla Williams, Gary Stack, Hong Gao, Dahui Zhou
  • Phenylpiperazine cycloalkanol derivatives and methods of their use
    Publication number: 20050143394
    Abstract: The present invention is directed to phenylpiperazine cycloalkanol derivatives, compositions containing these derivatives, and methods of their use for the prevention and treatment of conditions ameliorated by monoamine reuptake including, inter alia, vasomotor symptoms (VMS), sexual dysfunction, gastrointestinal and genitourinary disorders, chronic fatigue syndrome, fibromylagia syndrome, nervous system disorders, and combinations thereof, particularly those conditions selected from the group consisting of major depressive disorder, vasomotor symptoms, stress and urge urinary incontinence, fibromyalgia, pain, diabetic neuropathy, and combinations thereof.
    Type: Application
    Filed: October 12, 2004
    Publication date: June 30, 2005
    Applicant: Wyeth
    Inventors: Paige Mahaney, Eugene Trybulski, Lori Gavrin, An Vu
  • Stabilized difloxacin injectable solution
    Publication number: 20050143417
    Abstract: An antibacterial formulation suitable for injection into animals containing approximately 2-10% w/v difloxacin HCl, L-arginine base, propylene glycol, ethanol and/or benzyl alcohol, and water. The formulation is a solution having a pH of form 9 to 10. The formulation produces little or no tissue damage or irritation at the injection site.
    Type: Application
    Filed: March 3, 2005
    Publication date: June 30, 2005
    Applicant: WYETH
    Inventor: Henderik Frijlink
  • Oral administration of [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)alkyl] phosphonic acid and derivatives
    Publication number: 20050142192
    Abstract: Solid, pharmaceutical dosage forms of [2-(8,9-dioxo-2,6-diazabicyclo [5.2.0]non-1(7)-en-2-yl)alkyl]phosphonic acid and derivatives thereof are disclosed. In addition, methods of use are disclosed for the treatment, inter alia, of cerebral vascular disorders, anxiety disorders; mood disorders; schizophrenia; schizophreniform disorder; schizoaffective disorder; cognitive impairment; chronic neurodegenerative disorders; inflammatory diseases; fibromyalgia; complications from herpes zoster; prevention of tolerance to opiate analgesia; withdrawal symptoms from addictive drugs; and pain.
    Type: Application
    Filed: October 8, 2004
    Publication date: June 30, 2005
    Applicant: Wyeth
    Inventors: Eric Benjamin, William Cloud, Muhammad Ashraf, Mohammed Islam, Michael Brandt, Gerald Tremblay
  • Substituted aryl cycloalkanol derivatives and methods of their use
    Publication number: 20050143579
    Abstract: The present invention is directed to substituted aryl cycloalkanoyl derivatives, compositions containing these derivatives, and methods of their use for the prevention and treatment of conditions ameliorated by monoamine reuptake including, inter alia, vasomotor symptoms (VMS), sexual dysfunction, gastrointestinal and genitourinary disorders, chronic fatigue syndrome, fibromylagia syndrome, nervous system disorders, and combinations thereof, particularly those conditions selected from the group consisting of major depressive disorder, vasomotor symptoms, stress and urge urinary incontinence, fibromyalgia, pain, diabetic neuropathy, and combinations thereof.
    Type: Application
    Filed: October 12, 2004
    Publication date: June 30, 2005
    Applicant: Wyeth
    Inventors: Eugene Trybulski, Joseph Sabatucci, An Vu, Stephen Cohn, Arthur Santilli, Lori Gavrin, Fei Ye, Paige Mahaney
  • Novel modulator of non-genomic activity of nuclear receptors (mnar) and uses thereof
    Publication number: 20050142634
    Abstract: A novel protein modulator of non-genomic activity of nuclear receptors (MNAR), which interacts with estrogen receptors alpha (ER?), estrogen receptor beta (ER?), and other nuclear receptors, was discovered and characterized. An MNAR-ER complex, in vitro and in vivo, relates to nucleic acids, antisense, recombinant expression of nucleic acids, as well as host cells, compositions and assays that utilize the nucleic acids and protein of this invention.
    Type: Application
    Filed: April 3, 2002
    Publication date: June 30, 2005
    Applicant: Wyeth
    Inventors: Boris Cheskis, Elliott Nickbarg, Chi-Wai Wong
  • Heteroaryl, heterocyclic and aryl compounds which inhibit leukocyte adhesion mediated by VLA-4
    Patent number: 6911439
    Abstract: Disclosed are compounds which bind VLA-4. Certain of these compounds also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by VLA-4. Such compounds are useful in the treatment of inflammatory diseases in a mammalian patient, e.g., human, such as asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, tissue transplantation, tumor metastasis and myocardial ischemia. The compounds can also be administered for the treatment of inflammatory brain diseases such as multiple sclerosis.
    Type: Grant
    Filed: August 15, 2002
    Date of Patent: June 28, 2005
    Assignees: Elan Pharmaceuticals, Inc., Wyeth
    Inventors: Andrei W. Konradi, Michael A. Pleiss, Eugene D. Thorsett, Susan Ashwell, Gregory S. Welmaker, Anthony Kreft, Dimitrios Sarntakis, Darren B. Dressen, Francine S. Grant, Christopher Semko, Ying-Zi Xu
  • Antidepressant cycloalkylamine derivatives of heterocycle-fused benzodioxans
    Patent number: 6911445
    Abstract: Compounds of the formula: are useful for the treatment of depression (including but not limited to major depressive disorder, childhood depression and dysthymia), anxiety, panic disorder, post-traumatic stress disorder, premenstrual dysphoric disorder (also known as pre-menstrual syndrome), attention deficit disorder (with and without hyperactivity), obsessive-compulsive disorder, social anxiety disorder, generalized anxiety disorder, obesity, eating disorders, vasomotor flushing, cocaine and alcohol addiction, sexual dysfunction and related illnesses.
    Type: Grant
    Filed: September 10, 2003
    Date of Patent: June 28, 2005
    Assignee: Wyeth
    Inventors: Deborah Ann Evrard, Gary Paul Stack, Uresh Shantilal Shah
  • Extended release tablet formulations of venlafaxine
    Publication number: 20050136109
    Abstract: This invention relates to an extended release tableted dosage formulation of the antidepressant venlafaxine hydrochloride or an optical form thereof having improved bioavailability.
    Type: Application
    Filed: October 13, 2004
    Publication date: June 23, 2005
    Applicant: Wyeth
    Inventors: Michael Rowley, Angela Potts, Edward Sims
  • Carbon-carbon cross coupling catalyzed by transition metals on solid supports
    Publication number: 20050137438
    Abstract: The present invention provides methods of coupling carbon-containing compounds using a transition metal or transition metal complex on a solid support. The solid support can include alkaline earth metal salts, including carbonate and sulfate salts. The transition metals can include palladium or nickel metal. The method can include combining two carbon containing compounds and a transition metal or transition metal complex on a solid support in the presence of a solvent, desirably an alcohol.
    Type: Application
    Filed: November 22, 2004
    Publication date: June 23, 2005
    Applicant: Wyeth
    Inventor: Bogdan Wilk
  • Extended release pharmaceutical dosage form
    Publication number: 20050129762
    Abstract: This invention relates to novel extended release pharmaceutical dosage forms for orally delivering drugs to mammals, e.g., humans. More particularly, this invention concerns novel dosage forms of water soluble drugs such as venlafaxine, enantiomeric (R or S) forms of venlafaxine, metabolites of venlafaxine such as O-desmethyl venlafaxine (ODV) or enantiomeric (R or S) forms of said metabolites which dosage forms have an extended release profile when taken orally. This invention also provides processes for preparing such dosage forms and methods of using them.
    Type: Application
    Filed: October 13, 2004
    Publication date: June 16, 2005
    Applicant: Wyeth
    Inventors: Nicholas Heaton, Angela Potts, Ian Armstrong, James Provost